Recently, Bristol-Myers Squibb Company (BMY) received a boost with the European Commission (EC) approving Baraclude (entecavir) for an additional indication. The current approval by the European regulatory authorities allows Bristol-Myers to market Baraclude in 27 nations of the European Union for treating adults suffering from chronic hepatitis B (CHB) with decompensated liver disease. The US [...] (BMY) Bristol-Myers Squibb Earns European Clearance for Baraclude